Literature DB >> 19741460

TNF-alpha signaling is not required for in vivo transcriptional reactivation of latent murine cytomegalovirus.

Zheng Zhang1, Zhigao Li, Shixian Yan, Xueqiong Wang, Michael Abecassis.   

Abstract

BACKGROUND: Reactivation of cytomegalovirus (CMV) is frequently observed in recipients of solid organs and bone marrow transplants and is associated with increased risk of acute and chronic allograft rejection, opportunistic infection, graft failure, and patient mortality. The molecular mechanisms by which reactivation occurs are not well understood. Previous studies have suggested that tumor necrosis factor (TNF)-alpha, which is induced by allogeneic transplantation, may have a role in reactivation of CMV through activation of nuclear factor kappa-light-chain-enhancer of activated B cells and subsequent transcriptional reactivation of immediate early (ie) gene expression. METHODS AND
RESULTS: We have tested the role of TNF-alpha in the reactivation of CMV directly by testing whether TNF-alpha is required to initiate transcription of ie gene expression in a murine model of allogeneic transplantation of kidneys latently infected with mouse CMV.
CONCLUSIONS: Our studies show that although TNF-alpha seems to be sufficient, it is not required for initiating transcription of ie gene expression in this model, suggesting that both TNF-alpha-dependent and -independent pathways play an important role in the reactivation of latent CMV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741460      PMCID: PMC2747359          DOI: 10.1097/TP.0b013e3181b242a7

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  36 in total

1.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Focal transcriptional activity of murine cytomegalovirus during latency in the lungs.

Authors:  S K Kurz; M Rapp; H P Steffens; N K Grzimek; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

3.  Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome.

Authors:  C A Bolovan-Fritts; E S Mocarski; J A Wiedeman
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

4.  Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs.

Authors:  Christian O Simon; Christof K Seckert; Doris Dreis; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients.

Authors:  D Mutimer; D Mirza; J Shaw; K O'Donnell; E Elias
Journal:  Transplantation       Date:  1997-05-27       Impact factor: 4.939

6.  High incidence of active cytomegalovirus infection among septic patients.

Authors:  A S Kutza; E Muhl; H Hackstein; H Kirchner; G Bein
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

7.  Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency.

Authors:  M Hummel; Z Zhang; S Yan; I DePlaen; P Golia; T Varghese; G Thomas; M I Abecassis
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Human cytomegalovirus infections in nonimmunosuppressed critically ill patients.

Authors:  A Heininger; G Jahn; C Engel ; T Notheisen; K Unertl; K Hamprecht
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

9.  Serum cytokines in human heart transplant recipients. Is there a relationship to rejection?

Authors:  S C Grant; W R Lamb; N H Brooks; P E Brenchley; I V Hutchinson
Journal:  Transplantation       Date:  1996-08-27       Impact factor: 4.939

10.  Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model.

Authors:  Mary Hummel; Sunil M Kurian; Simon Lin; Aleksey Borodyanskiy; Zheng Zhang; Zhigao Li; Soo Jung Kim; Daniel R Salomon; Michael Abecassis
Journal:  Transplantation       Date:  2009-01-27       Impact factor: 4.939

View more
  5 in total

1.  A clinically relevant murine model unmasks a "two-hit" mechanism for reactivation and dissemination of cytomegalovirus after kidney transplant.

Authors:  Zheng Zhang; Longhui Qiu; Shixian Yan; Jiao-Jing Wang; Paul M Thomas; Manoj Kandpal; Lihui Zhao; Andre Iovane; Xue-Feng Liu; Edward B Thorp; Qing Chen; Mary Hummel; Yashpal S Kanwar; Michael M Abecassis
Journal:  Am J Transplant       Date:  2019-05-14       Impact factor: 8.086

2.  Transplant-induced reactivation of murine cytomegalovirus immediate early gene expression is associated with recruitment of NF-κB and AP-1 to the major immediate early promoter.

Authors:  Xue-Feng Liu; Chunfa Jie; Zheng Zhang; Shixian Yan; Jiao-Jing Wang; Xueqiong Wang; Sunil Kurian; Daniel R Salomon; Michael Abecassis; Mary Hummel
Journal:  J Gen Virol       Date:  2016-01-20       Impact factor: 3.891

3.  Human cytomegalovirus induces TGF-β1 activation in renal tubular epithelial cells after epithelial-to-mesenchymal transition.

Authors:  Masako Shimamura; Joanne E Murphy-Ullrich; William J Britt
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

Review 4.  New Insights Into the Molecular Mechanisms and Immune Control of Cytomegalovirus Reactivation.

Authors:  Taylor A Heald-Sargent; Eleonora Forte; Xuefeng Liu; Edward B Thorp; Michael M Abecassis; Zheng Jenny Zhang; Mary A Hummel
Journal:  Transplantation       Date:  2020-05       Impact factor: 5.385

Review 5.  Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response.

Authors:  Eleonora Forte; Zheng Zhang; Edward B Thorp; Mary Hummel
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.